A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infants

Grants and Contracts Details

StatusFinished
Effective start/end date5/5/09 → 6/30/11

Funding

  • Novartis (domestic): $3,843.00